MovDisordV3, Main, Exploration, bibRecord, 003197

Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial

Identifieur interne : 003197 ( Main/Exploration ); précédent : 003196; suivant : 003198

Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial

Auteurs : Jacques Montplaisir [Canada] ; Jeff Karrasch [Australie] ; Jean Haan [Allemagne] ; Dieter Volc [Autriche]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-10.

RBID : ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9

Descripteurs français

Pascal (Inist)
- Conduite à tenir, Essai clinique, Impatience membre inférieur syndrome, Long terme, Ropinirole, Système nerveux pathologie.

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Clinical management, Clinical trial, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Long term, Long-Term Care, Male, Middle Aged, Nervous system diseases, Restless Legs Syndrome (drug therapy), Restless legs syndrome, Ropinirole, Single-Blind Method, Treatment Outcome, long‐term management, randomized controlled clinical trial, restless legs syndrome, ropinirole.
MESH :
- chemical , adverse effects : Dopamine Agonists, Indoles.
- chemical , therapeutic use : Dopamine Agonists, Indoles.
- drug therapy : Restless Legs Syndrome.
- Adolescent, Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Long-Term Care, Male, Middle Aged, Single-Blind Method, Treatment Outcome.

Abstract

The objective of this study was to investigate the long‐term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single‐blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double‐blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double‐blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression–Improvement (CGI‐I) scale, change in International Restless Legs Scale (IRLS) score during double‐blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI‐I scores, sleep and QoL parameters with single‐blind ropinirole, which were better maintained when ropinirole was continued during the double‐blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long‐term management of RLS, with pharmacological effect over 36 weeks. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/ECEA56C61D08B8B6730CC0CD43272110B95065F9/fulltext/pdf

DOI: 10.1002/mds.21050

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21050</idno>
<idno type="url">https://api.istex.fr/document/ECEA56C61D08B8B6730CC0CD43272110B95065F9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000416</idno>
<idno type="wicri:Area/Istex/Curation">000416</idno>
<idno type="wicri:Area/Istex/Checkpoint">001C56</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Montplaisir J:ropinirole:is:effective</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16874755</idno>
<idno type="wicri:Area/PubMed/Corpus">002B40</idno>
<idno type="wicri:Area/PubMed/Curation">002B40</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002B02</idno>
<idno type="wicri:Area/Ncbi/Merge">001798</idno>
<idno type="wicri:Area/Ncbi/Curation">001798</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001798</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Montplaisir J:ropinirole:is:effective</idno>
<idno type="wicri:Area/Main/Merge">004510</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0538579</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001963</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001358</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001908</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Montplaisir J:ropinirole:is:effective</idno>
<idno type="wicri:Area/Main/Merge">004A03</idno>
<idno type="wicri:Area/Main/Curation">003197</idno>
<idno type="wicri:Area/Main/Exploration">003197</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Hôpital du Sacré‐Coeur de Montréal, Montréal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Peninsula Clinical Research Centre, Kipparing, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Neurologische Klinik, Schlafmedizinisches Zentrum, Moenchengladbach</wicri:regionArea>
<wicri:noRegion>Moenchengladbach</wicri:noRegion>
<wicri:noRegion>Moenchengladbach</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Confraternitaet–Privatklinik, Josefstadt, Wien</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-10">2006-10</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1627">1627</biblScope>
<biblScope unit="page" to="1635">1635</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">ECEA56C61D08B8B6730CC0CD43272110B95065F9</idno>
<idno type="DOI">10.1002/mds.21050</idno>
<idno type="ArticleID">MDS21050</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Clinical management</term>
<term>Clinical trial</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Long term</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Restless Legs Syndrome (drug therapy)</term>
<term>Restless legs syndrome</term>
<term>Ropinirole</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
<term>long‐term management</term>
<term>randomized controlled clinical trial</term>
<term>restless legs syndrome</term>
<term>ropinirole</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Conduite à tenir</term>
<term>Essai clinique</term>
<term>Impatience membre inférieur syndrome</term>
<term>Long terme</term>
<term>Ropinirole</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate the long‐term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single‐blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double‐blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double‐blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression–Improvement (CGI‐I) scale, change in International Restless Legs Scale (IRLS) score during double‐blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI‐I scores, sleep and QoL parameters with single‐blind ropinirole, which were better maintained when ropinirole was continued during the double‐blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long‐term management of RLS, with pharmacological effect over 36 weeks. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Canada</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
</noRegion>
</country>
<country name="Allemagne"><noRegion><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
</noRegion>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003197 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003197 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9
   |texte=   Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial

Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.